koto_feja/E+ via Getty Images
- Coya Therapeutics (NASDAQ:COYA) reported positive interim results from an open-label study testing a combination of low-dose IL-2 and CTLA4-Ig for the treatment of frontotemporal dementia.
- In the interim results of the first five patients, the treatment led to a significant and